pembrolizumab plus axitinib in the second-line and beyond for mrcc
Published 1 year ago • 81 plays • Length 4:40Download video MP4
Download video MP3
Similar videos
-
4:49
pembrolizumab plus axitinib and the future of further-line mrcc treatments
-
2:23
overview of a phase iii trial of pembrolizumab plus axitinib in rcc
-
4:47
keynote-426 - pembrolizumab plus axitinib versus sunitinib for mrcc
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
1:04
dr. rini discusses pembrolizumab plus axitinib in mrcc
-
2:26
இனி நோ கீமோ.. நோ சர்ஜரி..!! வந்துவிட்டது கேன்சருக்கான மருந்து..!! | cancer
-
5:09
recent advances in treating advanced kidney cancer
-
18:50
exploring the latest in renal cell cancer therapies with dr. monty pal using an algorithm
-
1:56
dr. cost on pembrolizumab plus axitinib in patients with rcc
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
1:00
adjuvant pembrolizumab for bladder cancer
-
1:03
dr. rini on managing the toxicity of pembrolizumab plus axitinib in mrcc
-
2:06
updated analysis of keynote-426: pembro plus axitinib vs sunitinib in mrcc
-
2:35
key data from asco gu 2019 on mrcc: pembrolizumab and axitinib as first-line therapy
-
1:40
dr. powles on fda approval of pembrolizumab plus axitinib in advanced rcc
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
0:49
clear: lenvatinib and pembrolizumab in advanced renal cell carcinoma
-
3:26
extended follow-up from a trial of pembrolizumab plus axitinib for advanced renal cell carcinoma
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
8:07
tki/io comparison: lenvatinib/pembrolizumab vs cabozantinib/nivolumab vs axitinib/pembrolizumab